413 reports of this reaction
1.8% of all EPOPROSTENOL SODIUM reports
#10 most reported adverse reaction
FLUSHING is the #10 most commonly reported adverse reaction for EPOPROSTENOL SODIUM, manufactured by GlaxoSmithKline LLC. There are 413 FDA adverse event reports linking EPOPROSTENOL SODIUM to FLUSHING. This represents approximately 1.8% of all 22,890 adverse event reports for this drug.
Patients taking EPOPROSTENOL SODIUM who experience flushing should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUSHING is a less commonly reported adverse event for EPOPROSTENOL SODIUM, but still significant enough to appear in the safety profile.
In addition to flushing, the following adverse reactions have been reported for EPOPROSTENOL SODIUM:
The following drugs have also been linked to flushing in FDA adverse event reports:
FLUSHING has been reported as an adverse event in 413 FDA reports for EPOPROSTENOL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUSHING accounts for approximately 1.8% of all adverse event reports for EPOPROSTENOL SODIUM, making it a notable side effect.
If you experience flushing while taking EPOPROSTENOL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.